Compare NTWK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | MREO |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 50.3M |
| IPO Year | 1997 | 2017 |
| Metric | NTWK | MREO |
|---|---|---|
| Price | $4.08 | $0.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 15.4K | ★ 4.9M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.67 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $73,088,687.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.40 | N/A |
| 52 Week Low | $2.73 | $0.20 |
| 52 Week High | $5.75 | $2.37 |
| Indicator | NTWK | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 41.21 |
| Support Level | $2.94 | $0.22 |
| Resistance Level | $4.53 | $0.35 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 58.37 | 23.45 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).